Meet ApplyKite Twin, the application assistant that learns with you
Meet your Twin, it learns with you
Your Twin learns with you
Launch week codes:30% off annual Pro20% off monthly Pro
Ends in00h00m00s
Ends in00h00m00s
Jesus Melgarejo
Has grant
Assistant Professor
Research Interests
Explore related searches
Recent Grants
Grant: Open
Study of 24-Hours Blood Pressure Data to Describe a Complex Cardiovascular Dynamic System Beyond Conventional Metrics
Open Date: 2025-04-01
Close Date: 2028-03-31
Articles (9)
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Aims Coronary artery disease (CAD) is multifactorial, caused by complex pathophysiology, and contributes to a high burden of mortality worldwide. Urinary proteomic analyses may help to identify predictive biomarkers and provide insights into the pathogenesis of CAD. Methods and results Urinary proteome was analysed in 965 participants using capillary electrophoresis coupled with mass spectrometry. A proteomic classifier was developed in a discovery cohort with 36 individuals with CAD and 36 matched controls using the support vector machine. The classifier was tested in a validation cohort with 115 individuals who progressed to CAD and 778 controls and compared with two previously developed CAD-associated classifiers, CAD238 and ACSP75. The Framingham and SCORE2 risk scores were available in 737 participants. Bioinformatic analysis was performed based on the CAD-associated peptides. The novel proteomic classifier was comprised of 160 urinary peptides, mainly related to collagen turnover, lipid metabolism, and inflammation. In the validation cohort, the classifier provided an area under the receiver operating characteristic curve (AUC) of 0.82 [95% confidence interval (CI): 0.78–0.87] for the CAD prediction in 8 years, superior to CAD238 (AUC: 0.71, 95% CI: 0.66–0.77) and ACSP75 (AUC: 0.53 and 95% CI: 0.47–0.60). On top of CAD238 and ACSP75, the addition of the novel classifier improved the AUC to 0.84 (95% CI: 0.80–0.89). In a multivariable Cox model, a 1-SD increment in the novel classifier was associated with a higher risk of CAD (HR: 1.54, 95% CI: 1.26–1.89, P < 0.0001). The new classifier further improved the risk reclassification of CAD on top of the Framingham or SCORE2 risk scores (net reclassification index: 0.61, 95% CI: 0.25–0.95, P = 0.001; 0.64, 95% CI: 0.28–0.98, P = 0.001, correspondingly). Conclusion A novel urinary proteomic classifier related to collagen metabolism, lipids, and inflammation showed potential for the risk prediction of CAD. Urinary proteome provides an alternative approach to personalized prevention.
Year:
2023
Collaborators (12)
Yan Cheng
Københavns Universitet
Esther Lopez-Garcia
Full Professor
Universidad Autónoma de Madrid
Dries Martens
Hasselt University
Claudia L Satizabal
Associate Professor
University of Texas Health Science Center at San Antonio
Tine Hansen
Professor
Copenhagen University Hospital
Kei Asayama
Professor
Teikyo University School of Medicine
Takayoshi Ohkubo
Teikyo University
Karlheinz Peter
MONASH UNIVERSITY
Silvia Mejia
Assistant Professor
The University of Texas Rio Grande Valley
Valérie Tikhonoff
Docenti di ruolo di IIa fascia
University of Padua
Kristina Vatcheva
associate professor
The University of Texas Rio Grande Valley
Zhen-Yu Zhang
Katholieke Universiteit Leuven
Make your next move.
Prepare your application
Review drafts before you send them.